Dr. Hoyng is described as an “excellent deal lawyer,” “an incredibly strong technician,” and “praised for his expertise in negotiating and drafting technology license agreements.”Chambers USA 2011

Charles F. Hoyng


Charles Hoyng is a partner in Latham & Watkins’ Boston and Silicon Valley offices and a member of the Life Sciences, Emerging Companies, and Intellectual Property and Technology Practice Groups. Dr. Hoyng's practice consists of negotiating and drafting life sciences technology license agreements and other similar agreements, and counseling in the development, protection, manufacture and distribution of products, particularly in the areas of:

  • Biotechnology 
  • Pharmaceutical products 

  • Medical diagnostic products 

  • Medical devices 

  • Healthcare related businesses

After earning his Ph.D. and prior to earning his law degree, Dr. Hoyng was a post-doctoral research fellow at the California Institute of Technology, Pasadena, California, an Assistant Professor of Chemistry at Texas A&M University, and held several positions at Genentech, Inc., including Director, Organic Chemistry, and Project Director for Genentech's tissue plasminogen activator (t-PA) project.

In addition to the bar qualifications listed above, Dr. Hoyng is licensed to practice law in the Northern District of California and the Court of Appeals, Ninth Circuit. Dr. Hoyng is a member of the American Bar Association.

Dr. Hoyng is recognized:

  • As one of the leading life sciences attorneys in the world by Chambers USA (2008 through 2011)
  • In The International Who’s Who of Business Lawyers 2009 guide

  • As a "recommended lawyer" for licensing transactions by Intellectual Asset Management (IAM), 2012

  • As a "Life Sciences Star" for transactional work by LMG (Legal Media Group) Life Sciences, 2012

  • As a "Super Lawyer" in intellectual property by Super Lawyers, Thomson Reuters, 2004, 2005, 2012

Speaking Engagements and Publications

Dr. Hoyng has lectured frequently and is the author of several articles on topics related to his practice. Representative speaking engagements include:

  • “Worldwide Company-University Collaborations," panelist at LESI 2012, Auckland, New Zealand, 2012
  • "M&A/Dealmaking – Is M&A and Licensing Good for the Biotech Industry?" panel moderator, at Bio InvestorForum 2006, San Francisco, California, 2006
  • "Pharmaceutical Co-Promotion and Co-Marketing Agreements in the US and Europe from a Biotech Perspective," panel moderator, at BayBio 2006: Accelerating Global Leadership, San Mateo, California, 2006
  • “Intellectual Property and Licensing,” at the New Jersey Stem Cell Research Economic Summit, New Jersey Stem Cell Research Endowment Fund, Newark, New Jersey, 2004
  • “Strategic Partnering and Licensing of Technology,” at International Biotechnology, M&A and Strategic Alliance, Tokyo, Japan, 2003
  • “Strategic Partnering” at Merrill Lynch Asia Pacific Biotechnology Seminar, Roadmap for an Initial Public Offering, Singapore, 2003
  • Practical Considerations in Licensing to and from Japanese Parties, The Journal of Proprietary Rights, Vol. 8, No. 6, June 1996
  • Education
    • JD, University of California, Berkeley, School of Law, 1989
    • PhD, Massachusetts Institute of Technology, 1976
    • BS, Miami University, 1972
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.